Don't miss this Thursday's July 14 live webcast from 12- 1 p.m.
When FDA talks about its cutting-edge research into 3D printing of FDA-regulated products.
For more information on the presentation and how to connect, go to the Grand Rounds web page.
About the Presentation
Additive manufacturing (AM)--also known as 3D printing--has created enormous potential in the medical product industries through newly enabled design possibilities and personalized medicine capabilities. FDA has cleared and approved several types of 3D-printed medical devices through its existing regulatory pathways and has also approved a 3D-printed drug product.
The speed of technology’s adoption has led to a growing need for 3D-printing best practices for medical products. FDA regulatory science research is helping the Agency develop an understanding of the unique technical aspects and challenges inherent in 3D printing and other emerging technologies to drive future innovation.
This presentation will provide a snapshot of research efforts internally and in collaboration with FDA academic partners. Some topics will include phantoms for device testing, patient-matched devices instrumentation, cleanability assessment, material optimization, and drug printing optimization.
FDA Grand Rounds
The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute presentation is followed by questions from the audience.